Biomaterials Science is a premier journal published by the Royal Society of Chemistry that serves as a leading platform for researchers and professionals in the fields of Biomedical Engineering and Materials Science. With an impressive impact factor bolstered by its Q1 quartile ranking in both disciplines, this journal has positioned itself at the forefront of cutting-edge research, showcasing innovative materials and applications that drive advancements in healthcare and technology. Since its inception in 2013, Biomaterials Science has been committed to disseminating high-quality, peer-reviewed articles that promote scientific knowledge and collaboration among academia and industry. With a global readership and a focus on open access, researchers are encouraged to share their findings to facilitate the development of transformative biomaterials and their applications. Join a vibrant community of scholars as we explore the future of biomaterials through this esteemed publication, enhancing both scientific inquiry and practical application.

Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

The Journal of Drug Delivery Science and Technology, published by Elsevier, stands at the forefront of pharmaceutical research, focusing on innovative drug delivery systems and technologies. With a robust impact factor reflected in its Q1 rating within the pharmaceutical sciences category, this journal is recognized for its high-quality contributions, ranking #30 out of 183 in the Scopus pharmacology and toxicology category (2023). Since its inception in 2004, the journal has been pivotal in disseminating groundbreaking research and advancements in drug formulation and delivery methodologies. Researchers and practitioners alike benefit from its comprehensive articles, which are accessible under open access options, ensuring widespread dissemination of knowledge. As it converges towards its 20th anniversary in 2024, the journal continues to enhance its impact on the scientific community, paving the way for future innovations in drug delivery.

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.